DNMT3A mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia vera.

Summary: Imagine you have a blood condition called polycythemia vera, where your body makes too many red blood cells. Doctors often treat this with a medicine called interferon alfa. Some patients have a specific change in their DNA called a DNMT3A mutation. Doctors wanted to know if this DNA change makes the medicine work less well. The good news? It doesn't! The medicine works just as well for people with or without this DNA change, and it doesn't change how long patients live.